Towards Healthcare Research & Consulting
Psychedelic Drugs Market
Updated Date: 25 June 2026   |   Report Code: 6885

Psychedelic Drugs Market Size, Growth Trends and Forecast 2026–2035

According to Shivani Zoting, who specializes in pharmaceutical and biotechnology market research, with 5+ years of experience in market research and industry analysis. My research indicates that the Psychedelic Drugs Market is set to grow from USD 6.68 billion in 2026 to USD 23.14 billion by 2035, driven by rising demand for innovative mental health treatments and expanding clinical development activities. I found that psilocybin, depression-focused therapies, oral formulations, hospitals, and psychedelic-assisted therapy represent the leading market segments, while North America maintains market leadership and Asia Pacific shows the strongest growth potential. The competitive landscape features companies such as Compass Pathways, Seelos Therapeutics, atai Life Sciences, GH Research, Johnson & Johnson, and Numinus Wellness, all advancing product development and commercialization strategies across the sector.

Last Updated : 25 June 2026 Category: Biotechnology Insight Code: 6885 Format: PDF / PPT / Excel

Content

Chapter 1: Introduction

  • Market Definition & Taxonomy
  • Research Objectives
  • Market Scope & Assumptions
  • Study Timeline (Historical, Base Year, Forecast Period)
  • Key Stakeholders Covered

Chapter 2: Research Methodology

  • Research Framework Overview
  • Market Size Estimation Methodology
    • Bottom-Up Approach
    • Top-Down Approach
  • Forecasting Model
    • Dependent Variables
    • Independent Variables
    • Key Assumptions & Weightages
  • Primary Research Insights
  • Secondary Data Sources
  • Data Validation & Triangulation

Chapter 3: Executive Summary

  • Global & Regional Overview (Value, CAGR)
  • Epidemiology Snapshot
  • Segmental Overview
  • Competition Key Snippets
  • Strategic Takeaways

Chapter 4: Market Catalysts, Constraints & Growth Levers

  • Market Dynamics
  • Market Drivers/Catalysts
    • Driver 1
    • Driver 2
  • Market Restraints
    • Restraint 1
    • Restraint 2
  • Market Opportunities
    • Opportunity 1
    • Opportunity 2
  • Market Trends
    • Trend 1
    • Trend 2
  • Impact Assessment of Drivers, Restraints, Opportunities & Trends (High, Mid, & Low)

Chapter 5: Value Added Intelligence

  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers: Low/Moderate/High
    • Bargaining Power of Buyers: Low/Moderate/High
    • Threat of New Entrants: Low/Moderate/High
    • Threat of Substitute: Low/Moderate/High
    • Competitive Rivalry: Low/Moderate/High
  • PESTEL Analysis
  • Ecosystem Analysis
  • Mapping of Key Players
  • Value Chain Analysis
  • Margin Analysis Across Value Chain
  • Macro & Micro Factors Impacting Market
  • Market Potential Evaluation, By Region
  • Epidemiology & Patient Pool Analysis
    • Disease Incidence & Prevalence
    • Target Patient Pool
      • Diagnosed Population
      • Service-Seeking Population
    • Patient Flow & Utilization Analysis
      • Patient Footfall
      • Admission Rates
      • Procedure Volume
    • Healthcare Infrastructure Analysis
      • Number of Facilities
        • Hospitals
        • Clinics
        • Diagnostic Centers
        • ASCs
      • Bed Capacity
        • Total Beds
        • ICU Beds
      • Facility Distribution
    • Operational Metrics Analysis
      • Bed Occupancy Rate (%)
      • Average Length of Stay (ALOS)
    • Service Pricing & Revenue Model
      • Pricing Analysis
        • Cost per Procedure
        • Cost per Consultation
        • Cost per Diagnostic Test
      • Revenue Streams
        • Inpatient Services
        • Outpatient Services
        • Ancillary Services
      • Workforce & Staffing Analysis
        • Healthcare Workforce
          • Physicians
          • Nurses
          • Technicians
        • Staff-to-Patient Ratios
        • Skill Gap Analysis
        • Labor Cost Structure
      • Scenario Analysis (Base / Optimistic / Pessimistic)
      • Risk Assessment & Sensitivity Analysis
      • Opportunity Analysis, By Region
      • Regulatory Analysis
      • Sustainability & ESG Insights
      • Business Models
      • Investment & Funding Landscape
      • Key Conferences and Events

Chapter 7: Segmental & Regional Analysis

  • Global Psychedelic Drugs Market Analysis, By Drug Type
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Psychedelic Drugs Market Analysis, By Application
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Psychedelic Drugs Market Analysis, By Route of Administration
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Psychedelic Drugs Market Analysis, By End User
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Psychedelic Drugs Market Analysis, By Treatment Model
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Psychedelic Drugs Market Analysis, By Molecule Source
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Psychedelic Drugs Market Analysis, By Distribution Channel
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Psychedelic Drugs Market Analysis, By Region
    • Market Size, Forecast & CAGR, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis
  • North America Psychedelic Drugs Market Analysis, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis, By Application, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis, By Route of Administration, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis, By End User, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis, By Treatment Model, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis, By Molecule Source, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis, By Distribution Channel, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Psychedelic Drugs Market Analysis, By Country, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
      • U.S. Psychedelic Drugs Market Analysis
    • U.S. Psychedelic Drugs Market Analysis, By Drug Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. Psychedelic Drugs Market Analysis, By Application, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. Psychedelic Drugs Market Analysis, By Route of Administration, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. Psychedelic Drugs Market Analysis, By End User, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. Psychedelic Drugs Market Analysis, By Treatment Model, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. Psychedelic Drugs Market Analysis, By Molecule Source, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. Psychedelic Drugs Market Analysis, By Distribution Channel, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis

Similar Analysis will be given for each country and each region

  • Canada
  • Mexico
  • Rest of North America

Europe

  • Western Europe
  • Germany
  • Italy
  • France
  • Spain
  • UK
  • Netherlands
  • Switzerland
  • Nordic Countries
  • Rest of Western Europe
  • Eastern Europe
  • Austria
  • Russia & Belarus
  • Poland
  • Türkiye
  • Rest of Eastern Europe

Asia Pacific

  • China
  • Taiwan
  • India
  • Japan
  • Vietnam
  • Australia and New Zealand
  • ASEAN Countries
  • South Korea
  • Rest of APAC

South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East and Africa (MEA)

  • GCC Countries
  • South Africa
  • Egypt
  • Rest of MEA

Chapter 6: Competitive Insights

  • Competitive Analysis
    • Company Evaluation Matrix
      • Major Players
      • Mid-Sized Companies
      • Emerging Players/Start-Ups
    • Global Market Share Analysis, By Region, 2025 (%)
    • Key Player Positioning
    • Competitive Benchmarking
      • By Drug Type
      • By Application
      • By Route of Administration
      • By End User
      • By Treatment Model
      • By Molecule Source
      • By Distribution Channel
    • Strategies of Key Players
    • Insight From the Horse’s Mouth
  • Company Profiles
    • Compass Pathways
      • Company Name
      • Company Headquarters
      • Management Overview
        • Key C-Suite Executives
          • CEO
          • MD
          • Others
        • Employee Count
        • Business Strategy
          • Key Investments Made
          • Future Plans
          • R&D & Innovation Capabilities
          • Recent Developments
            • New Product Launch
            • Merger & Acquisitions
            • Partnerships & Collaborations
            • Market Expansion
            • Others
          • Service Portfolio
          • Facility Network
            • Number of Facilities
            • Bed Capacity
            • Facility Distribution
            • Expansion Pipeline
          • Key Financials (2022-2025)
            • Revenue By Segment
            • Revenue By Service
            • Revenue By Geography
            • Financial Matrix (Gross Profit Margins, Net Margins, etc.)
          • Key Clients
            • Client Company Name
            • Key Contact Person
            • Contact Details
          • Regulatory & Certification Expertise
          • SWOT Analysis
    • Seelos Therapeutics
    • AtaiBeckley
    • GH Research
    • Definium Therapeutics
    • Enveric Biosciences
    • Helus Pharma
    • Optimi Health
    • Johnson & Johnson
    • Numinus Wellness

FAQ's

Answer : The psychedelic drugs market holds a valuation of USD 6.68 billion as of 2026, and will expand to USD 23.14 billion by 2035, achieving a CAGR of 14.8% between 2026 and 2035.

Answer : North America is currently leading the psychedelic drugs market by 46% due to favorable regulatory pathways that accelerate psychedelic drug approvals.

Answer : Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.

Meet the Team

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.

Learn more about Shivani Zoting

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar